Skip to main content
Fig. 2 | Retrovirology

Fig. 2

From: Moloney leukemia virus 10 (MOV10) inhibits the degradation of APOBEC3G through interference with the Vif-mediated ubiquitin–proteasome pathway

Fig. 2

MOV10 protects A3G from Vif-mediated degradation in wild-type HIV-1. a H9 cells were infected with pLKO.1-MOV10-shRNA or pLKO.1-Scr-shRNA lentivirus for 8 h and then selected with puromycin for 2 weeks. MOV10-knockdown H9 cells and control cells were infected with wild-type HIV-1 for 3 h and cultured with fresh medium for 12 days. The culture supernatants were collected at the indicated time points. Then HIV-1 p24 was detected using HIV-1 p24 ELISA kit at different time points (b). And at 12th day, these cells were analyzed by flow cytometer (c). HIV-1 p24 positive H9 cells were sorted and detected by western blotting with anti-MOV10, anti-A3G, anti-Vif, anti-HIV-1 p24, and anti-GAPDH antibodies (d). Values in d represent percentages of A3G or MOV10 normalized against GAPDH and compared with control. The bar graphs in d represent the average expression of A3G with different treatment and relative to the A3G-only reaction control (set to 100%). Data in a, b, and d represent mean ± SD from three independent experiments. *, statistically significant, p ≤ 0.05 (t test). All the results are representative of at least three independent experiments

Back to article page